This type of lymphoma is not frequently seen in the western hemisphere. Clinically, with the exception of anaplastic large cell lymphoma, mature T- and NK-cell lymphomas are among the most aggressive ...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for mature T-cell and NK-cell non-Hodgkin lymphoma is limited due to its rarity, affecting fewer than 10,000 individuals in the U.S. This scarcity results in fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. Additionally, the complex nature of lymphomas and their phenotypic overlap with other conditions further complicates characterization and understanding.
To navigate your care effectively, seek out a hematologist or oncologist with specific expertise in lymphomas, particularly those specializing in T-cell and NK-cell malignancies. While there are currently no identified patient organizations, you can access resources such as the Genetic and Rare Diseases Information Center at https://rarediseases.info.nih.gov for additional information. Participating in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
There are currently 131 active clinical trials investigating various aspects of mature T-cell and NK-cell non-Hodgkin lymphoma. Notable FDA-approved treatments include nivolumab and pembrolizumab, while several drugs are designated for development, such as anti-CD30 Fc engineered humanized monoclonal antibody. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=mature%20T-cell%20and%20NK-cell%20non-Hodgkin%20lymphoma.
Actionable guidance for navigating care for mature T-cell and NK-cell non-Hodgkin lymphoma
To navigate your care effectively, seek out a hematologist or oncologist with specific expertise in lymphomas, particularly those specializing in T-cell and NK-cell malignancies. While there are currently no identified patient organizations, you can access resources such as the Genetic and Rare Diseases Information Center at https://rarediseases.info.nih.gov for additional information. Participating in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for mature T-cell and NK-cell non-Hodgkin lymphoma is limited due to its rarity, affecting fewer than 10,000 individuals in the U.S. This scarcity results in fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. Additionally, the complex nature of lymphomas and their phenotypic overlap with other conditions further complicates characterization and understanding.
To navigate your care effectively, seek out a hematologist or oncologist with specific expertise in lymphomas, particularly those specializing in T-cell and NK-cell malignancies. While there are currently no identified patient organizations, you can access resources such as the Genetic and Rare Diseases Information Center at https://rarediseases.info.nih.gov for additional information. Participating in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
There are currently 131 active clinical trials investigating various aspects of mature T-cell and NK-cell non-Hodgkin lymphoma. Notable FDA-approved treatments include nivolumab and pembrolizumab, while several drugs are designated for development, such as anti-CD30 Fc engineered humanized monoclonal antibody. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=mature%20T-cell%20and%20NK-cell%20non-Hodgkin%20lymphoma.
Actionable guidance for navigating care for mature T-cell and NK-cell non-Hodgkin lymphoma
To navigate your care effectively, seek out a hematologist or oncologist with specific expertise in lymphomas, particularly those specializing in T-cell and NK-cell malignancies. While there are currently no identified patient organizations, you can access resources such as the Genetic and Rare Diseases Information Center at https://rarediseases.info.nih.gov for additional information. Participating in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for mature T-cell and NK-cell non-Hodgkin lymphoma is limited due to its rarity, affecting fewer than 10,000 individuals in the U.S. This scarcity results in fewer systematic clinical studies and a lack of comprehensive data on clinical features and genetic factors. Additionally, the complex nature of lymphomas and their phenotypic overlap with other conditions further complicates characterization and understanding.
To navigate your care effectively, seek out a hematologist or oncologist with specific expertise in lymphomas, particularly those specializing in T-cell and NK-cell malignancies. While there are currently no identified patient organizations, you can access resources such as the Genetic and Rare Diseases Information Center at https://rarediseases.info.nih.gov for additional information. Participating in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
There are currently 131 active clinical trials investigating various aspects of mature T-cell and NK-cell non-Hodgkin lymphoma. Notable FDA-approved treatments include nivolumab and pembrolizumab, while several drugs are designated for development, such as anti-CD30 Fc engineered humanized monoclonal antibody. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=mature%20T-cell%20and%20NK-cell%20non-Hodgkin%20lymphoma.
Actionable guidance for navigating care for mature T-cell and NK-cell non-Hodgkin lymphoma
To navigate your care effectively, seek out a hematologist or oncologist with specific expertise in lymphomas, particularly those specializing in T-cell and NK-cell malignancies. While there are currently no identified patient organizations, you can access resources such as the Genetic and Rare Diseases Information Center at https://rarediseases.info.nih.gov for additional information. Participating in clinical trials may also provide access to cutting-edge therapies and contribute to the understanding of this rare condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 15 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.